DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MEBENDAZOLE

Clinical Trials for Mebendazole

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00116493	Severe Anemia Treatment Trials, Pakistan	Completed	Aga Khan University	Phase 3	The purpose of this study is to test the efficacy of two enhanced regimens (deworming and multivitamins) in the treatment of severe anemia in pregnant women and children 6-24 months of age in Karachi, Pakistan.
NCT00116493	Severe Anemia Treatment Trials, Pakistan	Completed	Johns Hopkins Bloomberg School of Public Health	Phase 3	The purpose of this study is to test the efficacy of two enhanced regimens (deworming and multivitamins) in the treatment of severe anemia in pregnant women and children 6-24 months of age in Karachi, Pakistan.
NCT01050452	Safety and Efficacy of Drug Combinations Against Trichuris Trichiura	Completed	DBL -Institute for Health Research and Development	N/A	This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of albendazole (ALB), mebendazole (MBD) and ivermectin (IVM) separately, and ALB and MBD each in combination with IVM in the treatment of Trichuris trichiura in children aged 5-14 years.
NCT01173562	A Safety Study of Mebendazole in Children 2 to 10 Years of Age	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	The purpose of this study is to assess the safety and tolerability of mebendazole 500-mg chewable tablet formulation in a pediatric population. Mebendazole is a drug used for the treatment of soil-transmitted parasitic helminth (STH) (ie, parasitic worm) infections such as pinworm, whipworm, common roundworm, common hookworm, and American hookworm.
NCT01314937	The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Areas	Completed	Asociacion Civil Selva Amazonica	Phase 4	Worldwide, over 2 billion people suffer from worm infections in developing countries. These infections are especially damaging to the health of children, resulting in both short-term and lifelong disability. Older children with worm infections are more likely to be stunted, underweight, vulnerable to other illnesses and perform poorly in school compared to non-infected children. Large-scale deworming programs in school-age children are therefore recommended by the World Health Organization (WHO). WHO also recommends deworming of preschool-age children (as of 12 months of age) in these areas; however, the benefits of deworming, especially in the 12-24 month age group, have been inadequately studied. This knowledge is urgently needed as studies show that all children have a similar potential for healthy growth and development, provided that appropriate nutrition and health interventions are given in the critical window of opportunity before the age of two. Therefore, the investigators are proposing to undertake a randomized controlled trial to determine the effect of deworming program for improving growth and development in children between 12 and 24 months of age. Our results will provide solid rigorous evidence on if, when, and how often, deworming should be integrated into routine child health care packages provided by Ministries of Health in the 130 countries in the world where worm infections are endemic.
Trial ID	Title	Status	Sponsor	Phase	Summary